Arch Oncology Overview
- Founded
- 2006
- Status
- Private
- Employees
- 28
- Latest Deal Type
- Series C
- Latest Deal Amount
- $105M
- Investors
- 18
Arch Oncology General Information
Description
Developer of second-generation anti-CD47 antibodies designed to offer treatment for solid tumors. The company's antibodies represent a new class of checkpoint inhibitors that bridge the innate and adaptive immune systems to attack cancer, and it not only acts as an immune checkpoint inhibitor but also selectively kills tumor cells, helping patients with required treatment options to treat cancer.
Contact Information
Website
www.archoncology.com
Formerly Known As
Vasculox, Tioma Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Drug Delivery
Primary Office
- 2000 Sierra Point Parkway
- Suite 700
- Brisbane, CA 94005
- United States
+1 (415) 000-0000
Arch Oncology Timeline
Arch Oncology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Later Stage VC (Series C) | 27-Apr-2021 | $105M | 00000 | 00000 | Completed | Generating Revenue |
| 10. Later Stage VC (Series B) | 11-Mar-2021 | 0000 | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
| 9. Debt - PPP | 29-Apr-2020 | 00000 | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 8. Later Stage VC (Series B) | 25-Mar-2019 | 0000 | 000.00 | 0000 | Completed | Clinical Trials - Phase 1 |
| 7. Later Stage VC (Series A1) | 04-Feb-2018 | 00.00 | 000.00 | 000 | Completed | Pre-Clinical Trials |
| 6. Later Stage VC (Series A) | 04-Aug-2016 | 000.00 | 000.00 | 000.00 | Completed | Pre-Clinical Trials |
| 5. Grant | 29-Sep-2013 | 00000 | Completed | Pre-Clinical Trials | ||
| 4. Grant | 01-May-2013 | 00000 | Completed | Pre-Clinical Trials | ||
| 3. Grant | 01-May-2012 | $707K | Completed | Pre-Clinical Trials | ||
| 2. Grant | 01-Aug-2011 | $276K | Completed | Generating Revenue |
Arch Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | 00,000,000 | 00.000000 | 00.0 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series B | 00,000,000 | 00.000000 | 00.0 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A1 | 15,393,186 | $0.001000 | $0.06 | $0.69 | $0.69 | 1x | $0.69 | 8.22% |
Arch Oncology Executive Team (22)
Arch Oncology Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Carole Nuechterlein JD | Roche Venture Fund | Board Member | 000 0000 |
| Drew Dennison | Lightchain Capital | Board Member | 000 0000 |
| John Mckearn Ph.D | RiverVest Venture Partners | Chairman | 000 0000 |
| Julie Hambleton MD | Self | Board Member | 000 0000 |
Arch Oncology Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialArch Oncology Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Adage Capital Management | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Avego Healthcare Capital | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Broadfin Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Cowen Healthcare Investments | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Eventide Asset Management | Asset Manager | Minority | 000 0000 | 000000 0 |